Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis
Cutis · 01.01.2026 · 1 (117)
DOI: 10.12788/cutis.1301 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cutis, erschienen am 01.01.2026. Verfasst von Jerry Bagel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Psoriasis Treatment Center of Central New Jersey, East Windsor. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Psoriasis, Resorcinols, Stilbenes.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Psoriasis Treatment Center of Central New Jersey, East Windsor.
Zitieren
APA
Bagel, J., Hetzel, A., Reed, A., & Nelson, E. (2026). Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis. Cutis, 1(117). https://doi.org/10.12788/cutis.1301
Vancouver
Bagel J, Hetzel A, Reed A, Nelson E. Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis. Cutis. 2026;1(117). doi:10.12788/cutis.1301
BibTeX
@article{Bagel2026,
author = {Bagel, Jerry and Hetzel, Alexa and Reed, Ashley and Nelson, Elise},
title = {Safety and Effectiveness of Nonsteroidal Tapinarof Cream 1% Added to Ongoing Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis},
journal = {Cutis},
year = {2026},
volume = {1},
number = {117},
doi = {10.12788/cutis.1301}
}
EUVIMED